The present invention relates to pharmaceutical formulation in tablet form, containing nano sized Ursodeoxycholic acid (hereinafter referred as UDCA Nano) and the method of its preparation, wherein said formulation is characterized in its higher aqueous dispersibility & solubility and comparatively faster rate of me...
Documents
Directors report as per section 134(3)-17112020
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-17112020
List of share holders, debenture holders;-17112020
Form AOC-4-17112020_signed
Form MGT-7-17112020_signed
List of share holders, debenture holders;-08082019
Directors report as per section 134(3)-08082019
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-08082019
Form MGT-7-08082019_signed
Form AOC-4-08082019_signed
Form DPT-3-24062019
Form AOC-4-01102018_signed
Form MGT-7-01102018_signed
List of share holders, debenture holders;-24082018
Directors report as per section 134(3)-24082018
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-24082018
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-27032018
Directors report as per section 134(3)-27032018
Form AOC-4-27032018_signed
Form MGT-7-26032018_signed
Form ADT-1-24032018_signed
Optional Attachment-(1)-24032018
List of share holders, debenture holders;-24032018
Copy of written consent given by auditor-23032018
Copy of the intimation sent by company-23032018
Copy of resolution passed by the company-23032018
Optional Attachment-(1)-23032018
CERTIFICATE OF INCORPORATION PURSUANT TO CHANGE OF NAME-20170410